Penn LDI

pennldi.bsky.social

16 October 2026 13:23

This panel features experts: @dusetzinas.bsky.social of @vanderbilt.edu, LDI Fellow @hollylynchez.bsky.social of @penncareylaw.bsky.social, @dano-hta.bsky.social of of @icer-review.bsky.social, and LDI Fellow Emily Largent of @pennmehp.bsky.social.

Penn LDI

pennldi.bsky.social

16 October 2026 13:23

How should FDA-accelerated approval balance access, evidence, and cost? Join us on Oct. 22 for a panel on reforms, confirmatory studies, and the future of the pathway, co-sponsored by LDI, @pennmehp.bsky.social & the Center for Technology, Innovation & Competition. ldi.upenn.edu/events/the-u...

Dan Ollendorf

dano-hta.bsky.social

07 October 2026 14:41

A critically important topic for patients, deliberators, policymakers, and other interested parties to consider. Submit your comments on this public draft by November 2nd!

Any future FDA Commissioner will have to face eroding trust in our public health institutions. Accelerated approval accounts for a minority of approvals but encapsulates trends feeding mistrust, making a good starting point to restoring FDA’s credibility. www.healthaffairs.org/content/fore...

New from Institute for Clinical and Economic Review (ICER) and Verdant Research: We revisited our 2021 white paper on FDA's accelerated approval pathway. icer.org/news-insight...